Table 1.
Characteristics of included studies
| Study | Year | Design | Blinding | Abstract only | Population | N (NAC) | N (Placebo) |
|---|---|---|---|---|---|---|---|
| Barkholt et al. (15) | 2008 | RCT | No | No | Post-ASCT | 72 | 88 |
| Lee et al. (16) | 2009 | RCT | Double | No | Nonacetaminophen liver failure | 81 | 92 |
| Basu et al. (17) | 2013 | RCT | Unspecified | Yes | HILI | 30 | 30 |
| D’Amico et al. (18) | 2013 | RCT | Single | No | LT—donor | 69 | 71 |
| Nabi et al. (19) | 2017 | RCT | No | No | Nonacetaminophen liver failure | 40 | 40 |
| Grendar et al. (20) | 2016 | RCT | No | No | Hepatic resection | 96 | 110 |
| Kumar et al. (21) | 2017 | RCT | No | Yes | IH post-variceal bleed | 107 | 107 |
ASCT, allogeneic stem cell transplant; HILI, hypoxia-induced liver injury; IH, ischemic hepatitis; LT, liver transplant; N, number; NAC, N-acetylcysteine; RCT, randomized controlled trial.